In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

A trial exploring ... the two doses of semaglutide were comparable, while around a third of patients treated with 7.2mg achieved more than 25% weight loss. "Results from STEP UP further strengthen ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

How Long Does It Take for Semaglutide ... some of the weight-loss-promoting effects within your first few days or weeks of treatment. These effects include: In clinical trials of Wegovy ...

The drug also helped participants with weight loss ... causes, semaglutide offers a promising new approach for millions of patients.” The clinical trial involved participants with moderate to advanced ...

The findings are being hailed as a promising step ... impressive weight-loss benefits, contains the active ingredient semaglutide, also found in diabetes drug Ozempic. The clinical trial, funded ...